Edwin Moses | How to build large biotech platforms | E13

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow. 💎 ABOUT THE SPEAKER Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. I interviewed him back in 2018 when he sold the company. 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/edwin-moses-biotech-platforms/

🔗 LINKS MENTIONED

• Sanofi to acquire Ablynx for €3.9 Billion - https://www.sanofi.com/en/media-room/press-releases/2018/2018-01-29-07-19-03-1313306

Edwin Moses on stage in 2018 - https://www.youtube.com/watch?v=nWkd99rxVhc&t=802s&pp=ygUVZWR3aW4gbW9zZXMgbGFiaW90ZWNo 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS